Fund moves
50 tracked managers disclosed the same change for Q4 2025. From a 13F filed Apr 30, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Apr 1, 2026 · Filed Apr 3, 2026
A Regeneron Pharmaceuticals director sold $2.3K of Regeneron Pharmaceuticals shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$2,318
Shares × reported transaction price
61 days after results of Jan 30, 2026, 7 days before results of Apr 8, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $777.25 on Apr 1, 2026, within 5% of its 52-week high, after a 2% drop over the previous 30 trading days
52-week range $483.07 (Jun 5, 2025) to $812.27 (Jan 7, 2026), 89% of the way up, from 251 adjusted closes. 30 trading days earlier: $792.16 on Feb 18, 2026. Describes the past only, not a forecast
RSI 56, 17% above its 200-day average, 2% above its 50-day average, 4% below the 52-week high, 20-day volatility 28% a year, against the S&P 500: +5 points over 1 month, +5 points over 3 months, +40 points over 6 months
From the adjusted closes up to Apr 1, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Jan 7, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
In re Regeneron Pharmaceuticals, Inc. Securities Litigation, docket 1:25-cv-00145, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved Eylea HD on Apr 2, 2026, 1 day after this trade.
New use approved (efficacy supplement). Active ingredient: Aflibercept. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.2% | +4.1% | −6.3% |
| 30 days | −5.5% | +11.4% | −16.9% |
| 90 days | −14.8% | +14.0% | −28.9% |
| 180 days | −4.8% | +17.6% | −22.4% |
Past results only. Not a forecast.
Fund moves
50 tracked managers disclosed the same change for Q4 2025. From a 13F filed Apr 30, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
63 tracked managers disclosed the same change for Q1 2026. From a 13F filed Apr 30, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
63 tracked managers disclosed the same change for Q1 2026. From a 13F filed Apr 27, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.